Alzheimer Disease Clinical Trials in The Villages, Florida

4 studies are recruiting for alzheimer disease in The Villages, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

    This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.

    Stage
    Phase 2
    Ages
    55 to 90
    Site
    Charter Research - Lady Lake, The Villages, Florida
    Locations
    78 in total
    Run by
    Celgene

    See if you can join NCT06808984 on ClinicalTrials.gov

  2. A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

    The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.

    Stage
    Phase 3
    Ages
    55 to 90
    Site
    Charter Research, The Villages, Florida
    Locations
    293 in total
    Run by
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company

    See if you can join NCT06585787 on ClinicalTrials.gov

  3. A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease

    The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD). The study will also investigate how much LY3954068 gets into the bloodstream and will test the effects of LY3954068 on markers of AD. The study will be comprised of…

    Stage
    Phase 1
    Ages
    50 to 85
    Site
    Charter Research, LLC, The Villages, Florida
    Locations
    10 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT06297590 on ClinicalTrials.gov

  4. A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

    The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.

    Stage
    Phase 3
    Ages
    55 and older
    Site
    Charter Research - The Villages, The Villages, Florida
    Locations
    59 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT07602582 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.